Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase

British Journal of Pharmacology

Volumn 165, Issue 5, 2012, Pages 1487-1500

  Moroni, F ^a   Cozzi, A ^a   Chiarugi, A ^a   Formentini, L ^a   Camaioni, E ^b   Pellegrini Giampietro, D E ^a   Chen, Y ^c   Liang, S ^c   Zaleska, M M ^c   Gonzales, C ^c   Wood, A ^c   Pellicciari, R ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c PFIZER INC   (United States)

Author keywords

HYDAMTIQ; middle cerebral artery occlusion; neuroprotection; PARP; stroke; TIQ A

Indexed keywords

DIMETHYLAMINOMETHYL THIENO[2,3 C]ISOQUINOLIN 5 (4H)ONE; HYDROXY THIENO[2,3 C]ISOQUINOLIN 5 (4H)ONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; THIENO[2,3 C]ISOQUINOLIN 5 (4H)ONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION SIZE; CAROTID ARTERY OBSTRUCTION; CELL DIVISION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GENE; GENE DELETION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MITOSIS SPINDLE; NEUROPROTECTION; NONHUMAN; PARP GENE; PHARMACOPHORE; PRIORITY JOURNAL; RAT; STROKE; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; BRAIN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; HELA CELLS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; ISOQUINOLINES; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; STROKE; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 84863126436     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01666.x     Document Type: Article

References (51)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW, Sasaki M, et al,. (2006). Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci USA 103: 18308-18313.
3. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H, (1986). Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17: 472-476.
4. Berger NA, (1985). Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res 101: 4-15.
5. Caiafa P, Guastafierro T, Zampieri M, (2009). Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns. FASEB J 23: 672-678.
6. Chen ST, Hsu CY, Hogan EL, Maricq H, Balentine JD, (1986). A model of focal ischemic stroke in the rat: reproducible extensive cortical infarction. Stroke 17: 738-743.
7. Chiarugi A, (2002). Poly(ADP-ribose)polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol Sci 23: 122-129.
8. Chiarugi A, Moskowitz MA, (2003). Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 85: 306-317.
9. Chiarugi A, Meli E, Calvani M, Picca R, Baronti R, Camaioni E, et al,. (2003). Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J Pharmacol Exp Ther 305: 943-949.
10. Cipriani G, Rapizzi E, Vannacci A, Rizzuto R, Moroni F, Chiarugi A, (2005). Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction. J Biol Chem 280: 17227-17234.
11. Cosi C, Suzuki H, Milani D, Facci L, Menegazzi M, Vantini G, et al,. (1994). Poly(ADP-ribose)polymerase: early involvement in glutamate-induced neurotoxicity in cultured cerebellar granule cells. J Neurosci Res 39: 38-46.
12. Cozzi A, Cipriani G, Fossati S, Faraco G, Formentini L, Min W, et al,. (2006). Poly(ADP-ribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice. J Cereb Blood Flow Metab 26: 684-695.
13. De Murcia G, Menisser-de Murcia J, Schreiber V, (1992). Poly(ADP-ribose)polymerase: a molecular nick sensor. Trends Biochem Sci 19: 172-176.
14. De Ryck M, Van Reempts J, Borgers M, Wauquier A, Janssen PA, (1989). Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke 20: 1383-1390.
15. Dirnagl U, Iadecola C, Moskowitz MA, (1999). Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22: 391-397.
16. Egi Y, Matsuura S, Maruyama T, Fujio M, Yuki S, Akira T, (2011). Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia. Brain Res 1389: 169-176.
17. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, (1997). Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 3: 1089-1095.
18. Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA, (1997). Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase. J Cereb Blood Flow Metab 17: 1143-1151.
19. Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, et al,. (2008). Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis 25: 268-278.
20. Ferraris DV, (2010). Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem 53: 4561-4584.
21. Fisher M, (1999). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30: 2752-2758.
22. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al,. (2009). Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40: 2244-2250.
23. Fonfria E, Marshall IC, Benham CD, Boyfield I, Brown JD, Hill K, et al,. (2004). TRPM2 channel opening in response to oxidative stress is dependent on activation of poly(ADP-ribose) polymerase. Br J Pharmacol 143: 186-192.
24. Giovannelli L, Cozzi A, Guarnieri I, Dolara P, Moroni F, (2002). Comet assay as a novel approach for studying DNA damage in focal cerebral ischemia: differential effects of NMDA receptor antagonists and poly(ADP-ribose) polymerase inhibitors. J Cereb Blood Flow Metab 22: 697-704.
25. Ha HC, Snyder SH, (1999). Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 96: 13978-13982.
26. Haddad M, Beray-Berthat V, Coqueran B, Palmier B, Szabo C, Plotkine M, et al,. (2008). Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice. Eur J Pharmacol 588: 52-57.
27. Hagberg H, Wilson MA, Matsushita H, Zhu C, Lange M, Gustavsson M, et al,. (2004). PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem 90: 1068-1075.
28. Hottiger MO, Hassa PO, Luscher B, Schuler H, Koch-Nolte F, (2010). Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci 35: 208-219.
29. Jagtap P, Szabo C, (2005). Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4: 421-440.
30. Kauppinen TM, Swanson RA, (2005). Poly(ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death. J Immunol 174: 2288-2296.
31. Koh SH, Park Y, Song CW, Kim JG, Kim K, Kim J, et al,. (2004). The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals. Eur J Neurosci 20: 1461-1472.
32. Kraus WL, Lis JT, (2003). PARP goes transcription. Cell 113: 677-683.
33. Lenzser G, Kis B, Snipes JA, Gaspar T, Sandor P, Komjati K, et al,. (2007). Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats. J Cereb Blood Flow Metab 27: 1318-1326.
34. Lescot T, Fulla-Oller L, Palmier B, Po C, Beziaud T, Puybasset L, et al,. (2010). Effect of acute poly(ADP-ribose) polymerase inhibition by 3-AB on blood-brain barrier permeability and edema formation after focal traumatic brain injury in rats. J Neurotrauma 27: 1069-1079.
35. Liu X, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, et al,. (2008). An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem 381: 240-247.
36. Longa EZ, Weinstein PR, Carlson S, Cummins R, (1989). Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84-91.
37. McCullough LD, Zeng Z, Blizzard KK, Debchoudhury I, Hurn PD, (2005). Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J Cereb Blood Flow Metab 25: 502-512.
38. Moroni F, (2008). Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage. Curr Opin Pharmacol 8: 96-103.
39. Moroni F, Chiarugi A, (2009). Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment. FEBS J 276: 36-45.
40. Moroni F, Meli E, Peruginelli F, Chiarugi A, Cozzi A, Picca R, et al,. (2001). Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. Cell Death Differ 8: 921-932.
41. Moroni F, Attucci S, Cozzi A, Meli E, Picca R, Scheideler MA, et al,. (2002). The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death. Neuropharmacology 42: 741-751.
42. Moroni F, Formentini L, Gerace E, Camaioni E, Pellegrini-Giampietro DE, Chiarugi A, et al,. (2009). Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage. Br J Pharmacol 157: 854-862.
43. Pellicciari R, Camaioni E, Costantino G, Marinozzi M, Macchiarulo A, Moroni F, et al,. (2003). Towards new neuroprotective agents: design and synthesis of 4H-thieno[2,3-c] isoquinolin-5-one derivatives as potent PARP-1 inhibitors. Farmaco 58: 851-858.
44. Pellicciari R, Camaioni E, Gilbert AM, Macchiarulo A, Bikker JA, Shah F, et al,. (2011). Discovery and characterization of novel potent PARP-1 inhibitors endowed with neuroprotective properties: from TIQ-A to HYDAMTIQ. Med Chem Commun 2: 559-565.
45. Schreiber V, Dantzer F, Ame JC, de Murcia G, (2006). Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7: 517-528.
46. Szabo C, Dawson VL, (1998). Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 19: 287-298.
47. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al,. (2002). Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 297: 259-263.
48. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, et al,. (2006). Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 103: 18314-18319.
49. Yuan M, Siegel C, Zeng Z, Li J, Liu F, McCullough LD, (2009). Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke. Exp Neurol 217: 210-218.
50. Zhang Y, Dawson VL, Dawson TM, Snyder SH, (1994). Nitric oxide activation of poli(ADP-ribose)synthetase in neurotoxicity. Science 263: 687-689.
51. Zhang Y, Zhang X, Park TS, Gidday JM, (2005). Cerebral endothelial cell apoptosis after ischemia-reperfusion: role of PARP activation and AIF translocation. J Cereb Blood Flow Metab 25: 868-877.